Clinical trials: Depression Anxiety Disorder
Depression
Meru Health Program Versus Waitlist Control for Adults With Depression
This is a randomized controlled trial (RCT) of the Meru Health Program (MHP) versus a waitlist (WL) control group, which will be offered access to the MHP after the waitlist period (12 weeks) is over, for adults with depression.
- Trial name
- NCT04738084
- Testing
- Meru Health Program
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Meru Health, Inc.
Depression, Anxiety
Understanding the Efficacy of Mobile Apps as Intervention for Depression in Adults When Deployed as Part of Primary Care.
The clinical study is meant to optimize the mobile intervention, to develop a robust implementation plan for the mobile intervention within primary care, and to conduct an effectiveness trial, randomizing 128 participants in…
- Conditions
- Depression, Anxiety, Primary Health Care
- Trial name
- NCT03500536
- Testing
- IntelliCare
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Actualize Therapy
Depression, Anxiety
Aiberry AI Mental Health Screening Platform
Aiberry is creating a multi-modal artificial intelligence (AI) platform that analyzes facial, audio and text features to screen for mental illness.
- Conditions
- Depression, Anxiety, Healthy
- Trial name
- NCT04994899
- Where
- 3 sites in United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Aiberry, Inc
Depression Disorders, Anxiety Disorders
Pivotal U.S. Clinical Validation of AI-COA® for Depression and Anxiety
This study is a large-scale pivotal clinical validation of the AI-COA® software device. The purpose is to confirm the tool's accuracy and performance across a demographically diverse population of adults with Major Depressive…
- Trial name
- SEQUOIA-3 (NCT07279038)
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- Deliberate Solutions Inc.
Anxiety Depression
Probiotics Regulate Intestinal Health and Alleviate Anxiety
This study is a randomized, double-blind, placebo-controlled trial aimed primarily at investigating the effects of Weizmannia coagulans BC99 on alleviating anxiety and depression and the gut microbiota.
- Trial name
- NCT07353320
- Testing
- probiotics group
- Where
- China
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Mild Cognitive Impairment, Anxiety State
Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI
This Phase I/II clinical trial aims to test the effectiveness of a new sublingual formulation of 5-MeO-DMT in reducing symptoms of anxiety, depression, and cognitive decline in individuals with mild to moderate Alzheimer's…
- Conditions
- Mild Cognitive Impairment, Anxiety State, Depression Anxiety Disorder
- Trial name
- 5-MeO-DMT (NCT06812221)
- Testing
- Sublingual administration, Electroencephalography, Biochemical mesurements
- Where
- Argentina
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Biomind Labs Inc.
Anxiety Depression
Efficacy and Safety of Probiotics for Anxiety Depression
This randomized, double-blind, placebo-controlled study will enroll 60 individuals with mild-to-moderate anxiety depression. Following a 3-month intervention and a 1-month follow-up period, the study aims to: 1) evaluate the…
- Trial name
- NCT07331987
- Testing
- Probiotic, Escitalopram
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Moon (Guangzhou) Biotechnology Co., Ltd.
Major Depressive Disorder, Generalized Anxiety
Scaling Mental Healthcare in COVID-19 With Voice Biomarkers
This study aims to advance research on group sessions for mental health. The first-of-its-kind study measuring various features in a group setting, combining rich metadata in creating state-of-the-art machine learning models, and…
- Trial name
- NCT04510519
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Depressive Disorder, Major
An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms
The purpose of this study is to evaluate the efficacy and safety of long term escitalopram treatment in participants with Major Depressive Disorder (MDD) with associated anxiety symptoms.
- Trial name
- Lexapro (NCT01814098)
- Testing
- Escitalopram
- Where
- 10 sites in China
- Volunteers
- 318 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Adjustment Disorder
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to…
- Trial name
- NCT07002034
- Testing
- RE104 for Injection
- Where
- 32 sites in United States
- Volunteers
- 100 people
- Sponsor
- Reunion Neuroscience Inc
COVID-19, Pregnancy Complications
Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic
The purpose of this study is to assess the health and wellbeing of pregnant and recently pregnant women during the COVID-19 pandemic using an online survey.
- Conditions
- COVID-19, Pregnancy Complications, Mental Health Wellness 1, Anxiety
- Trial name
- NCT04385238
- Testing
- This is an online survey with no intervention.
- Where
- United States
- Volunteers
- 6,894 people
- Sponsor
- Pregistry
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder Co-Occurrent With Anxiety, Adult Patients
First choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic
According to the local guidelines (Recommendation for General Practitioners), the first choice Anti-Depressant (AD) in Major Depressive Disorder (MDD) in primary care should be selective serotonin reuptake inhibitors (SSRI), e.g.
- Conditions
- Major Depressive Disorder Co-Occurrent With Anxiety, Adult Patients, Newly Diagnosed Depression
- Trial name
- FIAT (NCT05291897)
- Where
- 6 sites in Czechia
- Volunteers
- 28 people
- Sponsor
- Angelini Pharma Česká republika s.r.o.
Long Covid, Depression
Development of an Accessible Cognitive Behavioral Therapy Digital Therapeutic for Individuals With Long COVID
This study will evaluate Toivoa-004 as an experimental digital therapeutic for persons with Long COVID suffering from anxiety or depression.
- Conditions
- Long Covid, Depression, Anxiety
- Trial name
- NCT07714889
- Testing
- Rauha® Digital Therapeutic Platform (Toivoa-004)
- Sponsor
- Toivoa Inc
Sleep, Pain
Radicle Health1: A Study of Health and Wellness Formulations and Their Effects on Overall Health
A randomized, blinded, placebo-controlled study of health and wellness product formulations and their effects on overall health
- Conditions
- Sleep, Pain, Depression, Anxiety
- Trial name
- NCT05783232
- Testing
- Health Active Study Product 1.1 Capsules, Health Active Study Product 1.2 Capsules, Health Active Study Product 1.3 Capsules
- Where
- United States
- Volunteers
- 1,494 people, healthy volunteers welcome
- Sponsor
- Radicle Science
Schizophrenia, Major Depressive Disorder
PHARMO Institute Seroquel Safety Study
The purpose of this observational study is to study specific outcomes of interest in users of quetiapine compared with all other atypical antipsychotics and specifically olanzapine and risperidone.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar Disorder, Generalized Anxiety Disorder
- Trial name
- PHARMO II (NCT01342120)
- Volunteers
- 18,325 people
- Sponsor
- AstraZeneca
Atopic Dermatitis
A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic
Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24. Description of the: Change in disease activity after 16 and 24 weeks Change in subject and family quality of…
- Trial name
- NCT05527964
- Where
- Czechia
- Volunteers
- 146 people
- Sponsor
- Sanofi
Premenstrual Syndrome (PMS)
Oxaloacetate Supplementation for Emotional PMS
Emotional Premenstrual Syndrome (PMS) affects millions of women worldwide. For Emotional PMS, including depression, anxiety, perceived stress and aggression, there are very few options.
- Trial name
- OAA4PMS (NCT03509714)
- Testing
- Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)
- Volunteers
- 48 people
- Sponsor
- Terra Biological LLC
Depressive Disorder and Anxiety Disorders
PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients
This six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in Seasonal Effective Disorder (SAD) patients, using functional brain imaging…
- Trial name
- NCT00343707
- Testing
- vestipitant, paroxetine
- Where
- Sweden
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Depressive Symptoms, Anxiety Disorders
Messaging Therapy for Depression and Anxiety: A Longitudinal Effectiveness Study
Therapies delivered via technology have been developed to improve accessibility, however, there is limited research regarding messaging therapy in particular, and none that we know of utilizing a longitudinal effectiveness…
- Trial name
- NCT03699488
- Testing
- psychotherapy via asynchronous message
- Volunteers
- 12,980 people
- Sponsor
- Talkspace